Presenters
Course Details
Due to the complexity and interaction of risk factors in patients with atrial fibrillation (AF), the management of this condition requires a comprehensive approach. In this webinar,
Dr. Maria Epifania Collantes (University of the Philippines – Philippine General Hospital) outlined the principles of guideline-directed AF management and the role of non-vitamin K oral anticoagulants in the prevention of ischemic stroke in patients with AF. She also shared the comprehensive clinical evidence of dabigatran, including data on both approved treatment doses. The webinar was chaired by Dr. Arnold Benjamin Mina (Adventist University of the Philippines College of Medicine).
About the speakers
Dr. Maria Epifania Collantes is an Associate Professor at the University of the Philippines (UP) College of Medicine and heads the Stroke Service of the UP-Philippine General Hospital. She is a Past President of the Stroke Society of the Philippines.
Dr. Arnold Benjamin Mina is a consultant in general internal medicine and cardiology and is a faculty of the Adventist University of the Philippines College of Medicine. He is a member of the Board of Directors of the Philippine Society of Hypertension.
Estimated time of Completion: 35 mins. 16 sec.
CPD Points: 0.5 Point
PRC Program No: PROG-2022-24718
Treatment Evolution: Practical Approach on SPAF Management Course Outline
- Global prevalence of AF
- Frequency of Atrial Fibrillation among Patient with Ischemic Stroke
- AF is associated with substantial morbidity and mortality
- Risk Factors for Atrial Fibrillation
- Global Burden of Stroke
- Risk factor for Stroke: Atrial Fibrillation
- VKAs have a narrow therapeutic window
- NOACs address many of the limitations of traditional therapies
- ESC 2020 Atrial Fibrillation Guidelines
- 2020 ESC guidelines for Diagnosis and Management of AF
- New Guideline Recommendations
- Recommendations for prevention of thrombo-embolic events in AF patients
- Assessing stroke risk: CHA2DS2-VASc
- NOACs are significantly more effective than warfarin, and furthermore the risk of stroke or SE in patients with AF
- NOAC vs. Warfarin in Atrial Fibrillation Studies
- Systemic stroke/embolization events
- Major bleeding events
- Gastrointestinal haemorrhage
- Summary of further RE-LY subgroups: Demographics
- Choosing the Right Dose for your AF Patients For Stroke Prevention
- EHRA 2021 Dosing Criteria
- EHRA 2021: NOAC Selection based on drug-drug interactions and/or risk of bleeding
- Does the use of low dose NOACs hoping to win on safety (i.e. Less bleeding) equate to efficacy?
- GLORIA-AF: a large prospective registry on the safety and effectiveness of dabigatran in the real world
- GLORIA-AF Phase III will continue to provide valuable, prospective, comparative real-world data on NOACs and VKAs
- Prospective data from GLORIA-AF supports the safety and effectiveness profiles of dabigatran in clinical practice
- When Life Happens (The Need for a Reversal Agent)
- Reversal Agents for NOACs
- What needs to be considered when choosing an appropriate OAC?
- Conclusion
PC-PH-103114 / August 2023